scholarly journals Population health, economics and ethics in the age of COVID-19

2020 ◽  
Vol 5 (7) ◽  
pp. e003259 ◽  
Author(s):  
Sanjay G Reddy

Are the steps that have been taken to arrest the spread of COVID-19 justifiable? Specifically, are they likely to have improved public health understood according to widely used aggregate population health measures, such as Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years (DALYs) as much or more than alternatives? This is a reasonable question, since such measures have been promoted extensively in global and national health policy by influential actors, and they have become almost synonymous with quantification of public health. If the steps taken against COVID-19 did not meet this test, then either the measures or the policies must be re-evaluated. There are indications that policies against COVID-19 may have been unbalanced and therefore not optimal. A balanced approach to protecting population health should be proportionate in its effects across distinct health concerns at a moment, across populations over time and across populations over space. These criteria provide a guide to designing and implementing policies that diminish harm from COVID-19 while also providing due attention to other threats to aggregate population health. They should shape future policies in response to this pandemic and others.

Author(s):  
Scott Burris ◽  
Micah L. Berman ◽  
Matthew Penn, and ◽  
Tara Ramanathan Holiday

Chapter 5 discusses the use of epidemiology to identify the source of public health problems and inform policymaking. It uses a case study to illustrate how researchers, policymakers, and practitioners detect diseases, identify their sources, determine the extent of an outbreak, and prevent new infections. The chapter also defines key measures in epidemiology that can indicate public health priorities, including morbidity and mortality, years of potential life lost, and measures of lifetime impacts, including disability-adjusted life years and quality-adjusted life years. Finally, the chapter reviews epidemiological study designs, differentiating between experimental and observational studies, to show how to interpret data and identify limitations.


2020 ◽  
Vol 36 (2) ◽  
pp. 96-103 ◽  
Author(s):  
Xue Feng ◽  
David D. Kim ◽  
Joshua T. Cohen ◽  
Peter J. Neumann ◽  
Daniel A. Ollendorf

ObjectivesQuality-adjusted life-years (QALYs) and disability-adjusted life-years (DALYs) are commonly used in cost-effectiveness analysis (CEA) to measure health benefits. We sought to quantify and explain differences between QALY- and DALY-based cost-effectiveness ratios, and explore whether using one versus the other would materially affect conclusions about an intervention's cost-effectiveness.MethodsWe identified CEAs using both QALYs and DALYs from the Tufts Medical Center CEA Registry and Global Health CEA Registry, with a supplemental search to ensure comprehensive literature coverage. We calculated absolute and relative differences between the QALY- and DALY-based ratios, and compared ratios to common benchmarks (e.g., 1× gross domestic product per capita). We converted reported costs into US dollars.ResultsAmong eleven published CEAs reporting both QALYs and DALYs, seven focused on pharmaceuticals and infectious disease, and five were conducted in high-income countries. Four studies concluded that the intervention was “dominant” (cost-saving). Among the QALY- and DALY-based ratios reported from the remaining seven studies, absolute differences ranged from approximately $2 to $15,000 per unit of benefit, and relative differences from 6–120 percent, but most differences were modest in comparison with the ratio value itself. The values assigned to utility and disability weights explained most observed differences. In comparison with cost-effectiveness thresholds, conclusions were consistent regardless of the ratio type in ten of eleven cases.ConclusionsOur results suggest that although QALY- and DALY-based ratios for the same intervention can differ, differences tend to be modest and do not materially affect comparisons to common cost-effectiveness thresholds.


2021 ◽  
Vol 24 (3) ◽  
pp. 353-360
Author(s):  
Maša Davidović ◽  
Nadine Zielonke ◽  
Iris Lansdorp-Vogelaar ◽  
Nereo Segnan ◽  
Harry J. de Koning ◽  
...  

Author(s):  
James Love-Koh ◽  
Andrew Mirelman ◽  
Marc Suhrcke

Abstract Distributional economic evaluation estimates the value for money of health interventions in terms of population health and health equity impacts. When applied to interventions delivered at the population and health system-level interventions (PSIs) instead of clinical interventions, additional practical and methodological challenges arise. Using the example of the Programme Saúde da Familia (PSF) in Brazil, a community-level primary care system intervention, we seek to illustrate these challenges and provide potential solutions. We use a distributional cost-effectiveness analysis (DCEA) approach to evaluate the impact of the PSF on population health and between-state health inequalities in Brazil. Data on baseline health status, disease prevalence and PSF effectiveness are extracted from the literature and incorporated into a Markov model to estimate the long-term impacts in terms of disability-adjusted life years. The inequality and average health impacts are analysed simultaneously using health-related social welfare functions. Uncertainty is computed using Monte Carlo simulation. The DCEA encountered several challenges in the context of PSIs. Non-randomized, quasi-experimental methods may not be powered to identify treatment effect heterogeneity estimates to inform a decision model. PSIs are more likely to be funded from multiple public sector budgets, complicating the calculation of health opportunity costs. We estimate a cost-per-disability-adjusted life years of funding the PSF of $2640. Net benefits were positive across the likely range of intervention cost. Social welfare analysis indicates that, compared to gains in average health, changes in health inequalities accounted for a small proportion of the total welfare improvement, even at high levels of social inequality aversion. Evidence on the population health and health equity impacts of PSIs can be incorporated into economic evaluation methods, although with additional complexity and assumptions. The case study results indicate that the PSF is likely to be cost-effective but that the inequality impacts are small and highly uncertain.


2021 ◽  
Vol 15 (8) ◽  
pp. e0009711
Author(s):  
Shuaibu Ahijo Abdullahi ◽  
Abdulrazaq Garba Habib ◽  
Nafiu Hussaini

A mathematical model is designed to assess the impact of some interventional strategies for curtailing the burden of snakebite envenoming in a community. The model is fitted with real data set. Numerical simulations have shown that public health awareness of the susceptible individuals on snakebite preventive measures could reduce the number of envenoming and prevent deaths and disabilities in the population. The simulations further revealed that if at least fifty percent of snakebite envenoming patients receive early treatment with antivenom a substantial number of deaths will be averted. Furthermore, it is shown using optimal control that combining public health awareness and antivenom treatment averts the highest number of snakebite induced deaths and disability adjusted life years in the study area. To choose the best strategy amidst limited resources in the study area, cost effectiveness analysis in terms of incremental cost effectiveness ratio is performed. It has been established that the control efforts of combining public health awareness of the susceptible individuals and antivenom treatment for victims of snakebite envenoming is the most cost effective strategy. Approximately the sum of US$72,548 is needed to avert 117 deaths or 2,739 disability adjusted life years that are recorded within 21 months in the study area. Thus, the combination of these two control strategies is recommended.


2019 ◽  
Vol 81 (02) ◽  
pp. 144-149
Author(s):  
Peter Morfeld ◽  
Thomas Erren

ZusammenfassungIn epidemiologischen Studien und deren Anwendung bei Schadstoffregulierungen (z. B. durch WHO, USA, EU) werden Wirkungen von Umweltexpositionen auf Bevölkerungen („Burden Of Disease“, „Krankheitslast“) oft mittels der verursachten „Anzahl vorzeitiger Todesfälle“, d. h. der durch die Exposition zeitlich vorverlagerten Todesfälle, quantifiziert. Ein aktuelles Beispiel ist die Studie von Schneider et al. zu Krankheitslasten durch Stickstoffdioxid (NO2)-Exposition in Deutschland, durchgeführt im Auftrag des Umweltbundesamtes. Die Autoren ermittelten den Anteil der durch die Exposition verursachten vorzeitigen Todesfälle mittels der „Attributablen Fraktion“ (AF). Gleichwohl können die wahren Zahlen vorzeitiger Todesfälle durch NO2 viel größer oder kleiner sein. Tatsächlich hatten Robins und Greenland bereits 1989 gezeigt, dass der AF-Ansatz nicht angemessen ist. Trotz der weitreichenden Bedeutung für Epidemiologie und Public Health wurde ihre wegweisende Arbeit nicht adäquat berücksichtigt, möglicherweise aufgrund der anspruchsvollen mathematischen Argumentation. Unser Beitrag erläutert – mit einfachen Methoden – unbeachtete aber bedeutende Fallstricke. Wir empfehlen, auf das Konzept der „Anzahl vorzeitiger Todesfälle“ zu verzichten und stattdessen die durch die Exposition verlorene Lebenszeit anzugeben, berechnet pro Person. Diese sollte aber nicht für unterschiedliche Todesursachen (Erkrankungen) und/oder Altersverteilungen aufgeschlüsselt werden. Wir zeigen zudem, dass „Disability Adjusted Life Years“ (DALY) kein angemessenes Maß sind, um Expositionswirkungen in der Bevölkerung zu bewerten.


Sign in / Sign up

Export Citation Format

Share Document